The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
Paying for healthcare costs could be among your biggest concerns after retiring. Here's how the possible tie-in might change the way you access care.
RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.
The chart for Diamondback Energy shows lots of positives. Here are several according to TheStreet's analysis.
A March poll contends that Big Pharma only trails large businesses in terms of the amount of clout it wields in Washington.
For Women's History Month, Alpha Rising is showcasing the women that have conquered Wall St. Today, meet Rosemary McFadden, the first woman to be president of a stock or futures exchange.
Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.